ARIA NEWS - 7:35 am Ariad Pharm announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (:NSCLC) who were previously treated with crizotinibBriefing.com(Tue 7:35AM EDT